<code id='F9F16A34CF'></code><style id='F9F16A34CF'></style>
    • <acronym id='F9F16A34CF'></acronym>
      <center id='F9F16A34CF'><center id='F9F16A34CF'><tfoot id='F9F16A34CF'></tfoot></center><abbr id='F9F16A34CF'><dir id='F9F16A34CF'><tfoot id='F9F16A34CF'></tfoot><noframes id='F9F16A34CF'>

    • <optgroup id='F9F16A34CF'><strike id='F9F16A34CF'><sup id='F9F16A34CF'></sup></strike><code id='F9F16A34CF'></code></optgroup>
        1. <b id='F9F16A34CF'><label id='F9F16A34CF'><select id='F9F16A34CF'><dt id='F9F16A34CF'><span id='F9F16A34CF'></span></dt></select></label></b><u id='F9F16A34CF'></u>
          <i id='F9F16A34CF'><strike id='F9F16A34CF'><tt id='F9F16A34CF'><pre id='F9F16A34CF'></pre></tt></strike></i>

          Home / comprehensive / explore

          explore


          explore

          author:knowledge    Page View:864
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In